Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies

Stock Information for Bionano Genomics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bionano Genomics Inc.

Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress
Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia
Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025
Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting
Bionano to Participate in the H.C. Wainwright @ Home Event
Bionano Genomics, Inc. Announces Closing of $10 Million Public O?ering
Bionano Genomics, Inc. Announces Pricing of $10 Million Public O?ering
Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.